Because BIM levels at tumour baseline can reflect the intensity of the PD-1/PD-L1 signalling pathway in tumour patients, and the method of detecting BIM levels is simpler than the ICH method for assessing PD-L1 expression, T-cell BIM level is expected to be a predictive biomarker. Here, BCL2L11 is linked to neoplasm.